STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
26.50
-0.22 (-0.82%)
At close: Oct 8, 2025, 4:00 PM EDT
26.85
+0.35 (1.32%)
After-hours: Oct 8, 2025, 5:11 PM EDT
STAAR Surgical Company Revenue
STAAR Surgical Company had revenue of $44.32M in the quarter ending June 27, 2025, a decrease of -55.23%. This brings the company's revenue in the last twelve months to $224.45M, down -32.59% year-over-year. In the year 2024, STAAR Surgical Company had annual revenue of $313.90M, down -2.64%.
Revenue (ttm)
$224.45M
Revenue Growth
-32.59%
P/S Ratio
5.82
Revenue / Employee
$193,992
Employees
1,157
Market Cap
1.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 27, 2024 | 313.90M | -8.51M | -2.64% |
| Dec 29, 2023 | 322.42M | 38.02M | 13.37% |
| Dec 30, 2022 | 284.39M | 53.92M | 23.40% |
| Dec 31, 2021 | 230.47M | 67.01M | 41.00% |
| Jan 1, 2021 | 163.46M | 13.28M | 8.84% |
| Jan 3, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
STAA News
- 6 hours ago - STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card - Business Wire
- 6 hours ago - Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon - Business Wire
- 9 hours ago - Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon - Business Wire
- 1 day ago - Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon - PRNewsWire
- 2 days ago - Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon - Business Wire
- 2 days ago - Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon - Business Wire
- 2 days ago - STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis - Business Wire
- 2 days ago - STAAR Surgical Addresses Broadwood Partners' Flawed, Misleading, and Misinformed Claims - Business Wire